21:27 , Aug 10, 2018 |  BC Extra  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus area...
20:45 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

Tracking TrkB agonists

It turns out that neurotrophic TrkB agonists used in many publications aren't TrkB agonists after all, according to a recent Science Signaling paper from Columbia University and the Broad Institute of MIT and Harvard. The...
16:22 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Extinguishing aversion

Last month in the Journal of Neuroscience, a team from the Chinese Academy of Sciences showed activating RAC1 could help treat opioid addiction by extinguishing the aversive memories of withdrawal that cause relapse in some...
14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: RAB3A member RAS oncogene family (RAB3A); brain-derived neurotrophic factor (BDNF)

Neurology INDICATION: Huntington's disease (HD) Mouse studies suggest promoting astrocyte RAB3A expression could help treat HD. In a mouse model of HD, transgenic expression of mouse RAB3A in striatal astrocytes increased BDNF secretion and decreased the number...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Brain-derived neurotrophic factor (BDNF); neurotrophic tyrosine kinase receptor 2 (TrkB; NTRK2); excision repair cross-complementation group 6 (ER

Neurology INDICATION: Leukodystrophy Patient sample and cell studies suggest BDNF, BDNF mimetics or other agonists of its receptor, TrkB, could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects in neurogenesis...
08:00 , Mar 3, 2016 |  BC Innovations  |  Targets & Mechanisms

Rescue mission

A pair of preclinical studies published last month on the autism target SHANK3 provide what might be the most meaningful progress for patients since the gene was linked with the disease over a decade ago....
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Cysteamine bitartrate delayed-release capsules: Additional Phase II/III data

Data from the open-label, crossover second part of the French Phase II/III CYST-HD trial in 96 HD patients showed that RP103 for 36 months slowed the rate of change in the TMS score component of...
07:00 , Aug 13, 2015 |  BC Innovations  |  Translation in Brief

Pain's he said/she said

Neurology Most preclinical studies are performed in male animals, but a new study suggests entirely different targets, pathways and cell types could be responsible for mechanical pain in males and females, and provides clues about why...
07:00 , Apr 9, 2015 |  BC Innovations  |  Targets & Mechanisms

Fat burning question

An oral mimetic of the neurotrophic growth factor BDNF has the unusual profile of breaking down fat while increasing food intake, according to preclinical findings from a group at Emory University. Most of the molecule's...